MIRA
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
MIRA Pharmaceuticals, Inc. (MIRA) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 9 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | D+ (1.8) | D (1.2) | C- (2.1) | C+ (2.6) | C- (2.1) |
| 2026-11-06 | C+ (2.5) | D+ (1.8) | D (1.2) | C- (1.9) | C+ (2.7) | C- (2.0) |
| 2026-10-30 | C+ (2.5) | D+ (1.8) | D (1.4) | C- (1.9) | C+ (2.7) | C- (2.1) |
| 2026-10-23 | C+ (2.5) | C- (1.9) | D (1.3) | D+ (1.8) | C+ (2.6) | C- (2.0) |
| 2026-10-16 | C+ (2.5) | D+ (1.8) | D (1.3) | D+ (1.5) | C+ (2.6) | C- (2.0) |